Stock QNRX QUOIN PHARMACEUTICALS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Delayed Nasdaq
Other stock markets
 16:54:01 29/04/2024 BST 		5-day change 1st Jan Change
0.65 USD +1.96% Intraday chart for Quoin Pharmaceuticals, Ltd. -1.52% -86.75%
03-15 Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating MT
03-14 Quoin Pharmaceuticals Seeks M&A Opportunities CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Quoin Pharmaceuticals Seeks M&A Opportunities
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Top Midday Decliners
Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall
Top Premarket Decliners
Top Midday Gainers
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Quoin Pharmaceuticals, Ltd. Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Quoin Pharmaceuticals Ltd. Enters into an Exclusive License and Distribution Agreement with Farma Mondo SA
Quoin Pharmaceuticals Limited Seeks M&A
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Quoin Pharmaceuticals Says it Dosed First Patient in Study of QRX003 for Netherton Syndrome
Quoin Pharmaceuticals, Ltd. Doses First Patient in Open Label Netherton Syndrome Clinical Trial
Quoin Pharmaceuticals Seeks M&A Opportunities
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QNRX Stock
  4. News Quoin Pharmaceuticals, Ltd.
  5. Other languages